Skip to main content
SpringerLink
Log in

New potential safety signals for CAR-T cell therapies

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Fusaroli M, et al. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database Drug Safety : 19 Jul 2022. Available from: URL: https://doi.org/10.1007/s40264-022-01194-z

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

New potential safety signals for CAR-T cell therapies. Reactions Weekly 1916, 10 (2022). https://doi.org/10.1007/s40278-022-19469-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-19469-y

Search

Navigation